The global tuberculosis drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor that is anticipated to augment the market during the forecast period includes an increase in R&D investments and an increase in new drug developments. For instance, a US-based TB Alliance, which is a non-profit organization, has developed a new drug for treating highly drug-resistant forms of tuberculosis. The TB Alliance received the US FDA approval in August 2019, for Pretomnid, a combination regimen with bedaquiline and linezolid, which is developed and indicated for the treatment of patients with XDR-TB, or intolerant non-responsive MDR-TB.
Further, to commercialize their newly developed drugs, the market players are focusing on strategic collaborations such as partnerships and collaborations, and mergers & acquisitions. For instance, in April 2019, Mylan NV, a pharmaceuticals company, collaborated with TB Alliance to commercialize the Pretomanid drug for treating pulmonary tuberculosis (TB). The other factor that is responsible for fuelling the market growth includes a high prevalence of TB across the globe. For instance, according to the World Health Organisation’s (WHO) global tuberculosis report 2018, around 10 million people globally suffered from Tuberculosis in 2017.
To Request a Sample of our Report on Global Tuberculosis Drugs Market: https://www.omrglobal.com/request-sample/tuberculosis-drugs-market
Tuberculosis (TB) is a chronic condition and has become a global disease burden. Manufacturers of TB drugs are focused on developing drugs that can shorten the duration of treatment, and support overcoming the challenges of drug-susceptible TB and drug-resistant TB. The treatment of TB is divided into three types, such as first-line therapy, second-line therapy, and combination therapy. Moreover, the other factor that is expected to propel the market growth includes the advent of novel therapies that are expected to improve the duration of treating TB.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: Johnson & Johnson Services, Inc., Lupin Ltd, Novartis International AG, Otsuka Pharmaceutical Co., Ltd, and Pfizer Inc.
(Get 15% Discount on Buying this Report)
A full Report of Global Tuberculosis Drugs Market is Available at: https://www.omrglobal.com/industry-reports/tuberculosis-drugs-market
Global Tuberculosis Drugs Market Report by Segment
By Therapy
• First-Line Therapy
• Second-Line Therapy
• Combination Therapy
By Disease Type
• Latent Tuberculosis
• Active Tuberculosis
Global Tuberculosis Drugs Market by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
